Transition from Clinical Trials into RWE in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylarthritis

المقدمة
سجل الان

الأهداف

Communicate Baricitinib and Ixekizumab value proposition in a speaker program setting in order to communicate what the product may mean to people living with Rheumatoid Arthritis Psoriatic Arthritis and Ankylosing Spondylarthritis diseases

المستهدفين :

Physician ( Internal Medicine , Rheumatology )

Resident / Fellow ( Internal Medicine , Rheumatology )

Clinical Pharmacy

Pharmacy

المتحدثين

Dr. Moayed Al Khalifah

Consultant Rheumatologist and Head of the Internal
Medicine Department at King Saud Hospital in Unaizah. He has presented at
regional and international rheumatology conferences, with research interests
spanning systemic autoimmune diseases and public health

Prof Suzan Attar

Professor & Consultant Rheumatologist in the Department of Internal Medicine at the King Abdulaziz University & King Abdulaziz University Hospital, Saudi Arabia. She is Board Certified at the Royal college of Physician and Surgeons of Canada (FRCPC) and Fellow of The American College of Rheumatology. Prof. Attar held numerous other roles: a member at Zaidi Chair of Rheumatic Disease, Editorial Member of several journals, and published research in multiple journals including in The Journal of Rheumatology and the European Journal of Rheumatology.

Dr. Hanan Al Rayes

1. Senior Consultant
2. President Saudi Society for Rheumatology
3. Deputy Director Medicine Department (PSMMC)
4. Director of Rheumatology fellowship program
5. Chairperson of evidence-based medicine committee
6- Founder of the Saudi Arthritis Registry
7- Chief Editor Annals of Arthritis and Autoimmunity Journal